Related coverage linked through entity extraction aliases.
Jul 19, 2026
Amgen detailed its T-cell engager and precision therapy strategy at Citi's 2026 summit. GT Biopharma, Onco-Innovations, Oncotelic, and Samsung Biologics also advanced AI and organoid platforms in drug development.
Apr 29, 2026
Global biologics market projected to grow to USD 1.28 trillion by 2035; Japan cell and gene therapy market to reach USD 2.15 billion by 2034; Japan biologic drug lifecycle management market to hit USD 9.69 billion by 2033.
Jul 25, 2026
A rare BTK A428D mutation causes resistance to all BTK-targeted therapies, finds a new study. China is reviewing the first CAR-T therapy for gastric cancer, and research reveals why BET inhibitors fail and targets AML's DNMT3A mutation.
Aug 08, 2026
The FDA approved Tregzi (Orca-T), a first-of-its-kind regulatory T cell-based immunotherapy, for adults with blood cancers undergoing matched donor stem cell transplants. Approval was based on the PRECISION-T trial, in which 78% of treated patients achieved chronic GVHD-free survival at one year versus 38.4% with standard transplant.
Jul 30, 2026
Zemcelpro (dorocubicel) has achieved NUB Status 1 in Germany, enabling hospitals to seek temporary reimbursement, while Cordex Biologics expanded access to Asia and Argentina through a distribution deal with FarmaMondo. The cell therapy holds conditional EU authorization for certain blood cancers.
Jul 30, 2026
The FDA granted RMAT designation to Allogene’s cema-cel for first-line LBCL consolidation and Cellectis’ lasme-cel for r/r B-ALL. Both allogeneic CAR-T therapies showed promising early efficacy and safety, with cema-cel also receiving Fast Track status.
Jul 21, 2026
The FDA has approved Tregzi, a donor-derived T-cell immunotherapy, to reduce the risk of chronic graft-versus-host disease following stem cell transplant in adults with high-risk blood cancers. In a pivotal trial, 78% of recipients were alive and free of severe chronic GVHD at one year versus 38.4% with standard transplant.
Jul 17, 2026
The FDA approved six cancer therapies in Q2 2026, including first-line sacituzumab govitecan for triple-negative breast cancer and capivasertib for PTEN-deficient prostate cancer. A separate study shows 69% of accelerated-approval cancer drugs need safety updates within 4 years.
Jul 11, 2026
The GE HealthCare-Mayo MI-BET collaboration advances biomarker-guided prostate cancer therapy. The precision oncology market, valued at $122.6B in 2025, is projected to reach $317.2B by 2034, fueled by genomics and targeted treatments.
Jun 29, 2026
Scientists have identified SLAMF6 as a key suppressor of T cell immunity against cancer and developed monoclonal antibodies that neutralize it in mice, published in Nature. Biotechnology company Replimune Group has reported its 2026 financial position, with a market value of approximately $234.5 million and ongoing clinical trials.
Jun 22, 2026
China has approved the world's first CAR-T cell therapy for solid tumors, specifically for stomach cancer, developed by CARsgen Therapeutics. Meanwhile, the WVU Cancer Institute has conducted the first-ever use of a subcutaneous formulation of blinatumomab to achieve remission in a patient with ultra-rare mixed phenotype acute leukemia.
Jun 22, 2026
Research estimates 300 million people worldwide live with rare diseases, yet only 5% of conditions have approved treatments. Patients face diagnostic delays of 4.7 to 8 years, with emerging AI and machine learning tools showing promise in accelerating diagnosis and drug development.
Jun 09, 2026
BostonGene announced a strategic collaboration with Daiichi Sankyo to integrate AI-driven analytics into an ADC development program. The company also revealed six abstracts will be presented at the EHA 2026 Congress in Stockholm. The research showcases integrated multiomics and predictive modeling for blood cancer treatment optimization.
Apr 23, 2026
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Apr 03, 2026
Researchers have engineered immune cells to sense cancer metabolites, improving tumor infiltration in solid cancers. Separate studies identify Kappa and Lambda Myeloma Antigens as specific targets for multiple myeloma treatment, while mRNA-based personalized cancer vaccines show promise through AI-driven neoantigen selection.
Apr 02, 2026
Two innovative CAR-T approaches show promise against solid tumors in preclinical studies. An in vivo gene editing system generates CAR-T cells directly in the body, while HLA-independent T cell receptors target CD70 across various tumor types. Both methods have demonstrated tumor clearance in mouse models, potentially expanding cell therapy applications beyond blood cancers.
Mar 06, 2026
Pfizer reported positive Phase 3 trial results for BRAFTOVI combination therapy in metastatic colorectal cancer and received FDA Priority Review for HYMPAVZI expansion to hemophilia patients including children.
Mar 06, 2026
AbbVie is testing venetoclax in a Phase 2 study for adults with relapsed or refractory Waldenström macroglobulinemia or lymphoplasmacytic lymphoma in Japan, aiming to expand the drug into rare blood cancers.
Feb 28, 2026
Researchers develop multiple strategies to enhance CAR T-cell therapy, including dual PGE2 receptor knockout for solid tumors and small-molecule switches using venetoclax and caffeine to control cellular activity and improve safety.
Feb 28, 2026
Recent studies demonstrate significant advances in engineered immune cell therapies, including enhanced CAR-T cells for solid tumors through NR2F6 deletion and mass production of CAR-NK cells from cord blood stem cells capable of generating millions of tumor-killing cells.
